Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Cubist, MorphoSys, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer’s disease, schizophrenia, diabetes, ADHD and chronic migraine.

Latest News

Mar 26, 2014

Heptares Presentation at Future Leaders in the Biotech Industry to be Webcast

Jan 23, 2014

Heptares Successfully Completes Research Phase Of Antibody Discovery Collaboration With MedImmune


Apr 23-24, 2014
Neurotech Investing & Partnering
Boston, MA, USA
Attending: Dan Grau

Apr 23-25, 2014
GTC Diabetes Summit
Cambridge, MA, USA
Presenting: Dan Grau

© 2012-2014 Heptares Therapeutics